← Eichor
Study identifier: NCT07688460 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers

Condition: Alzheimer Disease  ·  Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

PhasePhase 4
Planned participants100
Who can joinAll sexes, 50 Years to 90 Years
Healthy volunteersNo

About this study

This study aims to evaluate the therapeutic efficacy of Lecanemab in patients with Alzheimer's disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced electrochemiluminescence (ECL) to monitor specific biomarkers in the patients' plasma. By tracking changes in these biomarkers, the study seeks to determine how effectively Lecanemab treats the disease and to validate this new ECL-based monitoring system as a useful tool for clinical assessment.

This description comes directly from the study's public registry record.

Talk to the study team

Xuhua Xu  ·  +8613705790560  ·  fupinglangying@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital, Zhejiang University School of MedicineYiwu, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07688460